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A B S T R A C T
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic disorder, manifesting with monophasic or
relapsing course. Progressive course is rare in children. The article presents a boy with progressive generalized muscle
weakness and areflexia since the age of two, developed after viral infection. Electromyoneurography showed severe ne-
urogenic lesion, with myopathic pattern in proximal muscles. Increased serum ganglioside antibody titers (anti-GM1
and anti-GD1b) were registered. Sural nerve biopsy revealed demyelination and onion bulbs. Inflammatory perivascular
CD3 positive infiltrates were present in muscle and nerve biopsies. Brain magnetic resonance imaging showed cortical
atrophy, hyperintensities of the white matter and gray matter hypointensities. Improvement occurred on intravenous im-
mune globulins and methylprednisolone treatment. Demyelination might develop in central and peripheral nervous sys-
tem associated with inflammatory myopathy in patients with progressive course of CIDP.
Key words: chronic inflammatory demyelinating polyneuropathy, inflammatory myopathy, central nervous system,
child, antiganglioside antibody
Introduction
Chronic inflammatory demyelinating polyneuropathy
(CIDP) manifests itself with monophasic, relapsing or
progressive course. Children with CIDP present with
more severe clinical features than adults1. It is character-
ized by multifocal demyelination involving nerve roots,
intermediate nerve segments and nerve terminals. De-
myelinating changes of the brain have been reported in
some adult patients with CIDP2, and scarcely among pe-
diatric patients, mainly in the white matter3. The pa-
thogenesis of CIDP is still unknown, but involvement of
the immune system has been firmly established4. Differ-
ent ganglioside autoantibodies have been detected in
adults with CIDP5.
We present a case of a boy with early onset progres-
sive muscle weakness since the age of 2, associated with
focal central nervous system (CNS) involvement of white
and gray matter, inflammatory myopathy and positive
anti-GM1 ganglioside antibodies.
Case Report
A boy of normal psychomotor development, now at
the age of 10, was born after normal pregnancy and labor.
At the age of two he manifested progressive generalized
muscle weakness, hypotonia and small muscles hypo-
trophy, developed three weeks after viral infection. Elec-
tromyoneurography performed after six months showed
axonal lesion and mild loss of motoneurons and myo-
pathic pattern in proximal muscles. Muscle biopsy show-
ed muscle fiber regeneration and necrosis, perivascular
inflammatory infiltrates, and subsarcolemal accumula-
tion of mitochondria without visible structural abnor-
malities. Brain magnetic resonance imaging (MRI) show-
ed mild cortical atrophy, hyperintensities of the white
matter and the gray matter hypointensities, whereas
angiography was normal. He was treated with physio-
therapy, without improvement.
At the age of 4.5, examination revealed muscle weak-
ness (grade 4), generalized hypotonia and small muscles
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hypotrophy, peroneal gait, positive Gowers’ sign, are-
flexia, and right abducens palsy. Functional score of mo-
tor deficit was estimated according to Hughes grading
scale (grade 0 – healthy, grade 1 – minor signs or symp-
toms not interfering with normal social life, grade 2 –
able to walk without support of a stick but incapable for
manual work, grade 3 – able to walk 5 meters with assis-
tance, grade 4 – confined to bed or chairbound, grade 5 –
requiring assisted ventilation, grade 6 – dead)6. Elec-
tromyoneurography showed severe neurogenic lesion,
spontaneous activity, low compound muscle action poten-
tials (1 mV), decreased motor nerve conduction velocity
(7.9–11.3 m/s; normal values 56.14±4.96 m/s)7,8, prolon-
ged distal latency, and myopathic pattern in proximal
muscles. Cerebrospinal fluid examination revealed in-
creased protein content (0.40 g/L). Proton magnetic reso-
nance spectroscopy indicated decreased levels of N-acetyl-
-aspartat in cerebral cortex and increased lactate. Positive
serum anti-GM1 (IgM, 2000 Bühlmann Titer Units-BTU)
and anti-GD1b (IgG, 2300 BTU) antibodies were de-
tected. CK was 97–127 U/L (normal values 75–230 U/L at
37 °C). Follow-up brain MRI showed multiple white mat-
ter lesions, and repeated muscle biopsy showed neuro-
genic atrophy. Sural nerve biopsy revealed demyelination
and onion bulbs. Inflammatory perivascular CD3-posi-
tive infiltrates were present in both biopsies. Visual
evoked potentials showed bilaterally prolonged latencies.
Metabolic and immunological tests were normal, same as
aryl-sulphatase A and galactocerebrosidase activities. Mu-
tations for Charcot-Marie-Tooth disease 1A and hereditary
neuropathy with pressure palsies, as well as connexin
and spinal muscle atrophy mutations were excluded. Mi-
tochondrial genome analysis showed gene polymorphism
in sequence T13933A in ND5 gene, confirmed by mito-
chondrial genome sequencing. Methylprednisolone treat-
ment (1 mg/kg/day) induced significant improvement af-
ter four weeks. Tapering off the steroids, a few months
later, caused serious neurological impairment, so steroids
were reintroduced at a lower dose.
On examination at the age of 6, peroneal gait, positive
Gowers’ sign, muscle weakness (grade 2), small muscles
hypotrophy, areflexia, distal hypesthesia, left talocrural
and interphalangeal 5th finger contractures were pres-
ent. Follow-up electromyoneurography showed progres-
sion of the neural loss, inelicitable compound muscle ac-
tion potentials on the left peroneal nerve and very low
(250 µV) on the right, with prolonged distal latency and
completely absent sensory neural potentials. Further
clinical improvement occurred after intravenous immu-
ne globulins (IVIG) treatment (2 g/kg/5days). The follow-
ing electromyoneurography showed very low, but elici-
table left peroneal (250 µV), and increase of the amplitude
of the right peroneal compound muscle action potentials.
On examination at the age of 7.5, he manifested slight
improvement of muscle strength (grade 1), without addi-
tional changes in neurological examination. The recent
electromyoneurography, at the age of 9.5, showed in-
elicitable left peroneal nerve compound muscle action
potentials (Table 1 and Figure 1). Azathioprine was in-
troduced (1 mg/kg/day). He was treated with mainte-
nance steroid dose (0.5 mg/kg) on alternate day, azathio-
prine (1mg/kg/day) and periodic intravenous immune
globulins treatment (1 g/kg/3days) every 8–10 weeks.
Follow-up brain MRI and proton magnetic resonance
spectroscopy at the age of 8 showed improvement with
hyperintensities of the white matter mostly in frontal re-
gion (Figure 2).
Discussion
Our patient manifested limb girdle muscle weakness
and progressive small muscles atrophy associated with
CNS involvement. Electromyoneurographical findings
fulfilled diagnostic criteria for CIDP9,10, which was con-
firmed by nerve biopsy, whereas muscle biopsy showed
myopathy with perivascular inflammatory infiltrates.
CIDP manifests itself with broad heterogeneous clinical
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Fig. 1. Decreasing of compound muscle action potential ampli-
tude during long term follow-up recorded in extensor brevis mus-
Fig. 2. T2 – weighted brain magnetic resonance imaging (MRI)
coronal section (repetition time (TR), 5800.0 / echo time (TE), 90.0
ms). Hyperintensity of the white matter in left frontal region.
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and electrophysiological symptoms2. Axonal features are
observed rarely in children10. Children with CIDP mani-
fest more proximal muscle weakness11. The diagnosis of
CIDP in our patient was established according to pro-
posed electrophysiologic criteria by American Academy
of Neurology in 19919. His electromyoneurography show-
ed the conduction abnormalities in both distal and inter-
mediate segments with prolonged distal latencies more
than 125% of the upper limit, and pronounced decreasing
of motor nerve conduction velocity. Multifocal demy-
elination is a diagnostic hallmark of CIDP, but the degree
and distribution of demyelination is variable12. Recently,
conduction block/temporal dispersion have been pro-
posed as more sensitive and reliable electromyoneuro-
graphical criteria for the diagnosis of CIDP13. Other than
pronounced demyelinating polyneuropathy, electromyo-
neurography in our patient showed absent or very low
compound muscle action potentials, especially on distal
stimulation, suggesting severe and afterwards complete
axonal degeneration. Primary demyelination is the main
pathological feature in CIDP. However, axonal degenera-
tion in distal parts of the nerves was seen on autopsy in
patients with CIDP14. Axonal degeneration is often re-
sponsible for neurological impairment in autoimmune
and inherited disorders of central and peripheral ner-
vous system15. Distribution pattern of electrodiagnostic
abnormalities in inflammatory demyelinating polyne-
uropathies correlates with clinical features, response to
treatment and outcome12. In accordance with observa-
tion reported, our patient showed diffuse pattern with
slowly progressive and relapsing course.
Onion bulbs and inflammatory perivascular CD3 pos-
itive infiltrates were registered in his nerve biopsy. In-
flammatory infiltrates are registered often around epi-
neurial blood vessels, consisting of CD4 and CD8 T
lymphocytes10, thus suggesting the important role of the
cellular immunity in the pathogenesis of CIDP. Macro-
phages are involved in striping of the myelin from axons
with variable axonal loss.
Proximal muscle weakness, myopathic pattern in el-
ectromyoneurography and CD3 positive infiltrates in
muscle biopsy of our patient are compatible with the di-
agnosis of inflammatory myopathy. Normal CK values do
not exclude the muscle fibers involvement in our patient.
Polimyositis associated with CIDP has never been re-
ported. However, Kimura et al. described a boy with my-
asthenia gravis and CIDP, suggesting the spreading of
immune response from neuromuscular junction to pe-
ripheral nerve16.
Cerebrospinal fluid analysis of our patient revealed
slightly increased protein content (0.40 g/L, normal val-
ues up to 0.37 g/L) and suspected IgG intrathecal synthe-
sis, suggesting disfunction of the blood – cerebrospinal
fluid barrier surrounding the nerve roots.
IgG and IgM anti-GM1 antibodies were also present in
our patient as reported previously in adult patients with
CIDP5. The role of these antibodies in the pathogenesis
of the disease is unknown. Gangliosides may act as target
antigens in the immunopathogenesis of neuronal/myelin
damage. Our patient manifests both central and periph-
eral nervous system involvement. None of the reported
patients with CIDP and elevated IgM anti-GM1 antibod-
ies manifested definite CNS involvement, but showed
spontaneous activity and similar electrophysiological find-
ings as our patient17. In patients with amyotrophic lat-
eral sclerosis expression of antiganglioside antibodies
varies between 5.5–78%18,19 also suggesting that increas-
ed anti-GM1 IgM titers are closely associated with purely
motor or resembled motor neuron disease mostly revers-
ible by treatment.
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TABLE 1
FOLLOW UP OF NEUROGRAPHIC ABNORMALITIES
Age
(yrs.)
MNCV (m/s) CMAP (mV) DL (ms)


























































MNCV – motor nerve conduction velocity, CMAP – compound muscle action potential, DL – distal latency, M – median nerve, P –
peroneal nerve, S1- distal stimulation point, S2 – intermediate stimulation point, y – years, nd – not done, *normal values, #2 years af-
ter steroid treatment introduction, ##4 weeks after intravenous immunoglobulin (IVIG) treatment
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CNS involvement in CIDP presenting initially with
spinal symptoms and MRI intramedullary lesion has
been observed in the child. Later on, demyelination de-
veloped in the brain and peripheral nerves3. Differential
diagnosis of CIDP in children includes hereditary sen-
sory and motor neuropathies, leukodystrophies (meta-
chromatic, Krabbe) and other demyelinative disorders of
CNS, as well as aryl-sulphatase A pseudodeficiency20,
which were excluded in our patient. Some patients with
Charcot-Marie-Tooth disease show worsening and in-
flammatory infiltrates in their biopsies21 clinically re-
sponding to corticosteroids. It might also be possible that
patients with CIDP and mutations found in Charcot-Ma-
rie-Tooth disease manifest more pronounced symptoms22.
Some of the clinical symptoms in our patient resem-
ble mitochondrial encephalomyoneuropathies. CNS in-
volvement included radiological signs of both white and
gray matter. Proton magnetic resonance spectroscopy re-
vealed high lactate and decreased levels of N-acetyl-
-aspartate while the first biopsy performed at the age of 3
showed subsarcolemal accumulation of mitochondria with-
out visible structural abnormalities. Both of these find-
ings are not specific and might be present secondary
to different inflammatory conditions23,24,25. Visual evok-
ed potentials analysis showed signs of demyelinating op-
tic neuropathy. Optic neuropathy is not an uncommon
finding in CIDP. The association of a multiple sclerosis
(MS)-like disease and pathogenic Leber’s hereditary optic
neuropathy (LHON) mutations was reported previously
in several publications26,24,27. Very recently the pathology
of the MS-like lesions on autopsy was investigated in a
patient carrying the mitochondrial DNA 14484 patho-
genic LHON mutation28. Nuclear and mtDNA analysis in
our patient revealed only gene polymorphism, confirmed
by mitochondrial genome sequencing, thus excluding
pathogenetic role of mitochondrial DNA mutation.
Immunomodulating treatment has been shown to be
effective in children with CIDP10,1. IVIG is effective as
the first line therapy in CIDP according to the controlled
clinical trials. IVIG action in CIDP includes inhibition of
complement and membranolytic attack complex activa-
tion beside modulation of autoantibodies as well as of in-
hibition or activation of receptors29. Remissions are usu-
ally achieved after IVIG treatment but the vast majority
of patients still need additional intermittent IVIG treat-
ment at the dose 0.15–0.4 g/L every 6–8 weeks. The ta-
pering off the steroids in our patient resulted in clinical
deterioration and progression of small muscles atrophy.
Some authors reported steroid dependant course of re-
lapsing CIDP, which did not respond well to IVIG30.
Children with rapid progression of CIDP are more re-
sponsive to steroids30,10. Azathioprine has been shown to
be effective in the treatment of CIDP in children after
initial remission induction with steroids. None of the se-
rious side effects occurred during 12 years of follow-up10.
The efficacy of interferon b1 (a or b) still waits for proper
investigation of its place in treatment of CIDP.
Follow-up electromyoneurography showed slight im-
provement of distal compound muscle action potentials
in our patient after IVIG treatment, as previously re-
ported in adults31. Clinical improvement thus correlated
with resolution of conduction block in distal nerve seg-
ments. However, inelicitable peroneal nerve and severe
axonal loss were observed most recently in our patient.
Resistance to the treatment might be induced by the
axonal involvement during the long course of the ill-
ness12.
Clinical outcome and response to treatment are excel-
lent in children with CIDP, although electrodiagnostic
parameters of pronounced demyelination or axonal dam-
age might remain unchanged during long-term follow-
-up20.
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KRONI^NA UPALNA DEMIJELINIZIRAJU]A POLINEUROPATIJA PROGRESIVNOG TIJEKA U
DJE^AKA UDRU@ENA SA ZAHVA]ANJEM SREDI[NJEG @IV^ANOG SUSTAVA I MIOPATIJOM
S A @ E T A K
Kroni~na upalna demijeliniziraju}a polineuropatija se o~ituje monofazi~nim tijekom ili ponavljaju}im pogor{anjima
bolesti. Progresivan tijek bolesti u djece je rijedak. U ~lanku prikazujemo dje~aka sa progresivnom generaliziranom
mi{i}nom slabo{}u i arefleksijom, koja se razvila u dobi od 2 godine, nakon preboljele virusne infekcije. Elektromio-
neurografijom je na|eno te{ko neurogeno o{te}enje s miopatskim uzorkom u proksimalnim mi{i}nim skupinama. U
tijeku obrade dokazan je povi{eni titar serumskih protutijela na GM1 i GD1b gangliozide a pregledom biopta suralnog
`ivca potvr|ena je hipertrofi~na demijeliniziraju}a neuropatija i formacije poput lukovica. Upalni CD3 pozitivni infil-
trati na|eni su u bioptatima mi{i}a i `ivca. Magnetska rezonancija mozga pokazala je kortikalnu atrofiju, hiperin-
tenzitete bijele tvari i hipointenzitete sive tvari. Pobolj{anje je uslijedilo nakon intravenske primjene imunoglobulina i
terapije metilprednisolonom. Demijelinizacija se mo`e razviti u sredi{njem i perifernom `iv~anom sustavu udru`ena s
upalnom miopatijom u bolesnika s progresivnim tijekom kroni~ne upalne demijeliniziraju}e polineuropatije
N. Bari{i} et al.: CIDP with CNS Involvement and Myopathy in Child, Coll. Antropol. 30 (2006) 4: 945–949
949
U:\coll-antropolo\coll-antro-4-2006\Barisic.vp
20. prosinac 2006 9:59:40
Color profile: Disabled
Composite  150 lpi at 45 degrees
